Axsome Therapeutics Stock Rises 36% In A Month But Will The Rally Continue?

A couple of months back we discussed that Axsome Therapeutics stock is likely to rebound after it fell nearly 20% in a month following the U.S. FDA’s decision to pull the breakthrough therapy designation of AXS-12, the company’s drug used for the treatment of narcolepsy…

About the Author

has written 23527 stories on this site.

Copyright © 2010 corporatecommunicationsnews101.com